晚期子宫颈鳞癌同步放化疗后行18F-FDG PET/CT的作用
研究评估晚期子宫颈鳞癌患者同步放化疗后2-3个月行18F-FDG PET/CT的临床作用。55例中PET/CT阳性9例、可疑13例、阴性33例,阳性者均证实残留或转移并死亡,阳性与可疑者总生存差异显著,治疗前腹主动脉旁淋巴结阳性与治疗后PET/CT阳性相关并预示更差生存。
要点
- 治疗后2-3个月PET/CT阳性提示治疗失败,阳性者均证实残留或转移并死亡。
- 阳性与可疑PET/CT者总生存差异显著,可疑与阴性者无显著差异。
- 治疗前腹主动脉旁淋巴结阳性与治疗后PET/CT阳性相关并预示更差生存。
核心结论
- 治疗后2-3个月PET/CT阳性意味着治疗失败,需要新疗法以改善这类患者的结局。
- 治疗前腹主动脉旁淋巴结阳性的患者可能需要更密集的治疗后监测。
研究设计与样本
- 研究纳入参加前瞻性随机临床试验的晚期子宫颈鳞癌患者,评估同步放化疗后2-3个月行18F-FDG PET/CT的临床作用。
- 治疗后PET/CT结果分为阳性、可疑和阴性,比较不同结果患者的总生存率,并分析治疗前特征与治疗后PET/CT结果及预后的关联。
主要发现
- 55例患者的PET/CT结果中,阳性9例、可疑13例、阴性33例。
- 所有PET/CT阳性患者均证实存在残留或转移性疾病,尽管接受挽救治疗仍死亡。
- PET/CT阳性与可疑患者的总生存差异显著(P < .001),可疑与阴性患者之间无显著差异(P = .411)。
- 治疗前腹主动脉旁淋巴结阳性与治疗后PET/CT阳性相关(P = .033),并在治疗后PET/CT可疑或阴性的患者中预示更差的生存(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the clinical roles of [18F]fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) performed 2-3 months after completion of concurrent chemoradiotherapy (CCRT), along with pretherapy characteristics, in patients with advanced squamous cell carcinoma of the uterine cervix enrolled in a prospective randomized clinical trial. METHODS: Posttherapy PET/CT in patients with advanced FIGO stage or positive pelvic or para-aortic lymph node (PALN) defined on pretherapy PET/CT was classified as positive, equivocal, or negative. Overall survival (OS) rates between patients with different PET/CT results are compared. Pretherapy characteristics are examined for association with posttherapy PET/CT results and for prognostic significance in patients with equivocal or negative PET/CT. RESULTS: PET/CT scans (n = 55) were positive, equivocal and negative in 9, 13 and 33 patients, respectively. All patients with positive scans were confirmed to have residual or metastatic disease and died despite salvage therapies. There is a significant OS difference between patients with positive and equivocal scans (P < .001) but not between patients with equivocal and negative scans (P = .411). Positive pretherapy PALN is associated with positive posttherapy PET/CT (P = .033) and predicts a poorer survival in patients with equivocal or negative posttherapy PET/CT (P < .001). CONCLUSIONS: Positive PET/CT 2-3 months posttherapy implies treatment failure and novel therapy is necessary to improve outcomes for such patients. A more intense posttherapy surveillance may be warranted in patients with positive pretherapy PALN.
引用
- Liu FY, Su TP, Wang CC, et al. Roles of posttherapy 18F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018. PMID: 29470614. doi:10.1007/s00259-018-3957-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。